Ipilimumab pharmacotherapy in patients with metastatic melanoma

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 275-286

  Jeter, Joanne M ^a   Cranmer, Lee D ^a   Hersh, Evan M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

CTLA 4; Ipilimumab; Melanoma; Yervoy

Indexed keywords

ALPHA2B INTERFERON; ANTIDIARRHEAL AGENT; BEVACIZUMAB; BUDESONIDE; CANCER VACCINE; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DEXAMETHASONE; FREUND ADJUVANT; GLYCOPROTEIN GP 100; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; INFLIXIMAB; INTERLEUKIN 2; IPILIMUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; PREDNISOLONE ACETATE; PREDNISONE; STEROID; TEMOZOLOMIDE; TICILIMUMAB; VEMURAFENIB;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ANEMIA; ANTIGEN FUNCTION; APPETITE; ARTHRITIS; AUTOIMMUNE DISEASE; BLOODY DIARRHEA; BRAIN EDEMA; BRAIN METASTASIS; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLITIS; CONSTIPATION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENTEROCOLITIS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HORMONE SUBSTITUTION; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; IMMUNOTOXICITY; INTESTINE PERFORATION; INVASIVE ASPERGILLOSIS; LIVER METASTASIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN TOXICITY; SYSTEMIC DISEASE; UVEITIS; VASCULITIS; VITILIGO;

EID: 84865047961     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7245     Document Type: Review

References (36)

1. Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989;7(4):477.
2. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907.
3. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307(15):913.
4. Cranmer LD, Hersh E. The role of the CTLA-4 blockade in the treatment of malignant melanoma. Cancer Investigation. 2007;25:613-31.
5. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. Jul 17, 2000;192(2): 303-10.
6. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. Aug 1994;1(5): 405-13.
7. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. Jun 1, 1996;183(6):2541-50.
8. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. Jun 1, 1996;183(6):2533-40.
9. Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res. Feb 15, 2006;66(4):2442-50.
10. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. Mar 22, 1996;271(5256):1734-6.
11. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. Jul 22, 1997;94(15):8099-103.
12. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A. Dec 21, 1999;96(26):15074-9.
13. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A. Aug 18, 1998;95(17):10067-71.
14. Gorelik L, Prokhorova A, Mokyr MB. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother. Aug 1994; 39(2):117-26.
15. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. Aug 2, 1999;190(3):355-66.
16. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. Sep 17, 2001;194(6):823-32.
17. Gregor PD, Wolchok JD, Ferrone CR, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. Apr 16, 2004;22(13-14):1700-8.
18. White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest. Oct 2000;106(8):929-34.
19. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol. Oct 2010;37(5):450-4.
20. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. Apr 15, 2003;100(8):4712-7. Epub Apr 7, 2003.
21. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. Jul 8, 2003;100(14): 8372-7. Epub Jun 25, 2003.
22. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. Sep 1, 2005;23(25):6043-53. Epub Aug 8, 2005.
23. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. Feb 1, 2005;23(4):741-50. Epub Dec 21, 2004.
24. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTLassociated antigen-4 blockade. Clin Cancer Res. Nov 15, 2007;13(22 Pt 1): 6681-8. Epub Nov 2, 2007.
25. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. Apr 1, 2012;18(7):2039-47. Epub Jan 23, 2012.
26. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. Dec 2005;12(12):1005-16. Epub Oct 21, 2005.
27. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. Dec 20, 2008;26(36):5950-6. Epub Nov 17, 2008.
28. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. Aug 19, 2010;363(8):711-23. Epub Jun 5, 2010.
29. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. Jun 2011;29(3):489-98. Epub Jan 16, 2010.
30. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. Jun 30, 2011; 364(26):2517-26. Epub Jun 5, 2011.
31. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. Dec 1, 2009;15(23):7412-20. Epub Nov 24, 2009.
32. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. Sep 1, 2009;15(17):5591-8. Epub Aug 11, 2009.
33. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. May 2009;58(5): 823-30. Epub Feb 6, 2009.
34. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. Epub May 21, 2012.
35. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. Feb 15, 2011;17(4):896-906. Epub Nov 24, 2010.
36. Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. Dec 2011;21(6): 530-4.